Xuan Zhu1, Emma R Leof2, Kari G Rabe1, Jennifer B McCormick3, Gloria M Petersen1, Carmen Radecki Breitkopf4. 1. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. 2. Infectious Disease Epidemiology, Prevention, and Control Division, Minnesota Department of Health, St. Paul, Minnesota, USA. 3. Department of Humanities, College of Medicine, Pennsylvania State University, Hershey, Pennsylvania, USA. 4. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA, RadeckiBreitkopf.Carmen@mayo.edu.
Abstract
OBJECTIVES: Little is known about genetic research participants' responses to receiving individual research results (IRR) from cancer genetic research. We examined the immediate and delayed psychological impact of returning a CDKN2A variant result that is associated with increased risk of pancreatic cancer and melanoma. METHODS: One hundred and thirty-three pancreas research registry enrollees whose samples were tested in a research laboratory for the CDKN2A variant were invited by mail to learn the result by telephone and participate in a study about the disclosure process. Self-rated health, quality of life, and emotional responses were surveyed before and 6 months after disclosure. Genetic testing-specific distress, uncertainty, and positive experiences were assessed 6 months after disclosure. RESULTS: Eighty individuals agreed to participate; 63 completed the study. Both carriers and noncarriers showed no change over time in self-rated health, quality of life, or anxiety levels. Carriers reported more sadness than noncarriers before and 6 months after disclosure. Both carriers and noncarriers showed more hopefulness 6 months after than before disclosure. Carriers experienced greater test-specific distress and uncertainty than noncarriers, but levels were low. -Conclusions: Return of IRR in conjunction with cancer prevention counseling led to low levels of test-specific distress and uncertainty among carriers. No other adverse psychological outcomes were observed.
OBJECTIVES: Little is known about genetic research participants' responses to receiving individual research results (IRR) from cancer genetic research. We examined the immediate and delayed psychological impact of returning a CDKN2A variant result that is associated with increased risk of pancreatic cancer and melanoma. METHODS: One hundred and thirty-three pancreas research registry enrollees whose samples were tested in a research laboratory for the CDKN2A variant were invited by mail to learn the result by telephone and participate in a study about the disclosure process. Self-rated health, quality of life, and emotional responses were surveyed before and 6 months after disclosure. Genetic testing-specific distress, uncertainty, and positive experiences were assessed 6 months after disclosure. RESULTS: Eighty individuals agreed to participate; 63 completed the study. Both carriers and noncarriers showed no change over time in self-rated health, quality of life, or anxiety levels. Carriers reported more sadness than noncarriers before and 6 months after disclosure. Both carriers and noncarriers showed more hopefulness 6 months after than before disclosure. Carriers experienced greater test-specific distress and uncertainty than noncarriers, but levels were low. -Conclusions: Return of IRR in conjunction with cancer prevention counseling led to low levels of test-specific distress and uncertainty among carriers. No other adverse psychological outcomes were observed.
Authors: Ellen R Gritz; Susan K Peterson; Sally W Vernon; Salma K Marani; Walter F Baile; Beatty G Watts; Christopher I Amos; Marsha L Frazier; Patrick M Lynch Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: David Cella; Chanita Hughes; Amy Peterman; Chih-Hung Chang; Beth N Peshkin; Marc D Schwartz; Lari Wenzel; Amy Lemke; Alfred C Marcus; Caryn Lerman Journal: Health Psychol Date: 2002-11 Impact factor: 4.267
Authors: B Meiser; V Collins; R Warren; C Gaff; D J B St John; M-A Young; K Harrop; J Brown; J Halliday Journal: Clin Genet Date: 2004-12 Impact factor: 4.438
Authors: Colin B Begg; Irene Orlow; Amanda J Hummer; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Stephen B Gruber; Hoda Anton-Culver; Roberto Zanetti; Richard P Gallagher; Terence Dwyer; Timothy R Rebbeck; Nandita Mitra; Klaus Busam; Lynn From; Marianne Berwick Journal: J Natl Cancer Inst Date: 2005-10-19 Impact factor: 13.506
Authors: Gloria M Petersen; Mariza de Andrade; Michael Goggins; Ralph H Hruban; Melissa Bondy; Jeannette F Korczak; Steven Gallinger; Henry T Lynch; Sapna Syngal; Kari G Rabe; Daniela Seminara; Alison P Klein Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-04 Impact factor: 4.254
Authors: Jean Jenkins; Kathleen A Calzone; Eileen Dimond; David J Liewehr; Seth M Steinberg; Oxana Jourkiv; Pam Klein; Peter W Soballe; Sheila A Prindiville; Ilan R Kirsch Journal: Genet Med Date: 2007-08 Impact factor: 8.822
Authors: Henry T Lynch; Carrie Snyder; Jane F Lynch; Peggy Karatoprakli; Abdon Trowonou; Kelly Metcalfe; Steven A Narod; Gordon Gong Journal: Cancer Genet Cytogenet Date: 2006-03
Authors: Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Mwenza Blell; Isabelle Budin-Ljøsne; Lorraine Cowley; Stephanie O M Dyke; Clara Gaff; Robert Green; Alison Hall; Amber L Johns; Bartha M Knoppers; Stephanie Mulrine; Christine Patch; Eva Winkler; Madeleine J Murtagh Journal: PLoS One Date: 2021-11-08 Impact factor: 3.240
Authors: Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Madeleine J Murtagh Journal: Per Med Date: 2021-04-06 Impact factor: 2.512